Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
Open Access
- 24 May 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 12 (5), 417-424
- https://doi.org/10.1038/tpj.2011.18
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyThrombosis and Haemostasis, 2012
- Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trialClinical Trials, 2010
- Gamma-glutamyl carboxylase and its influence on warfarin doseThrombosis and Haemostasis, 2010
- Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin TherapyClinical Chemistry, 2009
- Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapyBlood Cells, Molecules, and Diseases, 2009
- Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsJournal of Thrombosis and Haemostasis, 2008
- CYP4F2 genetic variant alters required warfarin dosePublished by American Society of Hematology ,2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007